EPAS1 and nonpapillary renal cell carcinoma: Due to the observed effect of Tempol on HIF2α, CA9 and VEGF, all previously reported therapeutic targets for CCRCC tumors, we investigated whether Tempol might have an anti-tumor effect in CCRCC cells.